MX2015014046A - Combinaciones de farmacos para tratar cancer. - Google Patents
Combinaciones de farmacos para tratar cancer.Info
- Publication number
- MX2015014046A MX2015014046A MX2015014046A MX2015014046A MX2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A
- Authority
- MX
- Mexico
- Prior art keywords
- treat cancer
- drug combinations
- cancer
- treat
- cabozantinib
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 abstract 1
- 229960000853 abiraterone Drugs 0.000 abstract 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001292 cabozantinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808516P | 2013-04-04 | 2013-04-04 | |
| PCT/US2014/033008 WO2014165779A1 (en) | 2013-04-04 | 2014-04-04 | Drug combinations to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015014046A true MX2015014046A (es) | 2016-05-16 |
Family
ID=50732309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014046A MX2015014046A (es) | 2013-04-04 | 2014-04-04 | Combinaciones de farmacos para tratar cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160082019A1 (OSRAM) |
| EP (1) | EP2983639A1 (OSRAM) |
| JP (1) | JP2016515628A (OSRAM) |
| KR (1) | KR20150138268A (OSRAM) |
| CN (1) | CN108472242A (OSRAM) |
| AU (1) | AU2014248001A1 (OSRAM) |
| BR (1) | BR112015025408A8 (OSRAM) |
| CA (1) | CA2908815A1 (OSRAM) |
| HK (1) | HK1221424A1 (OSRAM) |
| MX (1) | MX2015014046A (OSRAM) |
| WO (1) | WO2014165779A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2758030C (en) | 2009-01-16 | 2019-01-08 | Exelixis, Inc. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| BR112015023109A2 (pt) | 2013-03-15 | 2018-05-15 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CA2939546C (en) | 2014-02-14 | 2023-01-17 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| MA40386A (fr) | 2014-07-31 | 2016-02-04 | Exelixis Inc | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
| CN117205313A (zh) * | 2017-01-20 | 2023-12-12 | 埃克塞里艾克西斯公司 | 治疗癌症的卡博替尼与阿特珠单抗组合 |
| EP3740210A4 (en) * | 2018-01-19 | 2022-02-16 | Indiana University Research and Technology Corporation | THERAPEUTIC TARGETING OF ANDROGEN RECEPTOR PHOSPHORYLATION INDUCED BY A TYROSINE KINASE RECEPTOR INHIBITOR IN CANCER |
| CA3088200A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
| KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2651730T3 (es) | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| EP1773826A4 (en) * | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| RS52956B (sr) * | 2006-08-25 | 2014-02-28 | Janssen Oncology Inc. | Kompozicije za tretman kancera |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| CA2758030C (en) * | 2009-01-16 | 2019-01-08 | Exelixis, Inc. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| WO2011009095A1 (en) * | 2009-07-17 | 2011-01-20 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2621481B2 (en) * | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| CN103664778B (zh) * | 2013-11-27 | 2017-04-05 | 苏州摩尔医药有限公司 | 一种抗肿瘤治疗药物卡博替尼的合成方法 |
-
2014
- 2014-04-04 JP JP2016506653A patent/JP2016515628A/ja active Pending
- 2014-04-04 BR BR112015025408A patent/BR112015025408A8/pt not_active IP Right Cessation
- 2014-04-04 KR KR1020157030445A patent/KR20150138268A/ko not_active Withdrawn
- 2014-04-04 MX MX2015014046A patent/MX2015014046A/es unknown
- 2014-04-04 CA CA2908815A patent/CA2908815A1/en not_active Abandoned
- 2014-04-04 WO PCT/US2014/033008 patent/WO2014165779A1/en not_active Ceased
- 2014-04-04 EP EP14724594.8A patent/EP2983639A1/en not_active Withdrawn
- 2014-04-04 US US14/782,493 patent/US20160082019A1/en not_active Abandoned
- 2014-04-04 HK HK16109729.1A patent/HK1221424A1/zh unknown
- 2014-04-04 AU AU2014248001A patent/AU2014248001A1/en not_active Abandoned
- 2014-04-04 CN CN201480029297.2A patent/CN108472242A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014165779A1 (en) | 2014-10-09 |
| EP2983639A1 (en) | 2016-02-17 |
| CA2908815A1 (en) | 2014-10-09 |
| HK1221424A1 (zh) | 2017-06-02 |
| US20160082019A1 (en) | 2016-03-24 |
| JP2016515628A (ja) | 2016-05-30 |
| CN108472242A (zh) | 2018-08-31 |
| KR20150138268A (ko) | 2015-12-09 |
| AU2014248001A1 (en) | 2015-11-19 |
| BR112015025408A8 (pt) | 2018-07-10 |
| BR112015025408A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2022001105A (es) | Anticuerpos anti tigit. | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2015011899A (es) | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. | |
| MX366978B (es) | Conjugados de anticuerpo - farmaco. | |
| MX2015011606A (es) | Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer. | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX2015011428A (es) | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. | |
| EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| IN2014MU00303A (OSRAM) | ||
| PH12015502342A1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| IN2013MU03118A (OSRAM) | ||
| GB2546703A (en) | Compounds | |
| MY182434A (en) | Certain chemical entities, compositions, and methods |